REGULATORY

MHLW Panel to Review Gilead’s Biktarvy, GSK’s Trelegy and More on Feb. 22

February 12, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Gilead Sciences’ HIV triplet known as Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate (TAF)) overseas and a throng of other drugs will come up for discussion by a key health ministry panel on February 22. If the thumbs-up is…

To read the full story

Kymriah Pre-Treatment Regimens Up for Review on Feb. 22
February 12, 2019

REGULATORY

Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…